Disease Landscape and Forecast Insights

Market Overview Ocrevus is the latest disease-modifying therapy (DMT) to launch for the treatment of relapsing forms of multiple sclerosis (MS) in the United States, and easily one of the most…

A large array of clinically unique disease-modifying therapies (DMTs) is approved for the treatment of multiple sclerosis (MS) in the United States. Competition in this crowded market has…

An increasing number of clinically unique disease-modifying therapies (DMTs) have been approved for the treatment of relapsing forms of multiple sclerosis (MS), the most prevalent form of MS…

In a landmark FDA ruling, Ocrevus became the first DMT approved for the treatment of PP-MS in March 2017. Although the drug’s efficacy appears more modest than in patients with relapsing forms of…

With its launch in August 2016, Zinbryta became the 14th disease-modifying therapy (DMT) approved to treat relapsing forms of multiple sclerosis (MS) in the United States. The monoclonal antibody…

Ocrevus is the 15th disease-modifying therapy (DMT) to launch for the treatment of relapsing forms of multiple sclerosis (MS) in the United States. Its novel B-cell-depleting mechanism offers…

The maturing but highly lucrative market for MSDMTs continues to fragment as new entrants propel ongoing shifts in a complicated treatment algorithm. Roche/Genentech’s Ocrevus will intensify…

With the availability of over a dozen disease-modifying therapies (DMTs) to treat multiple sclerosis (MS), the treatment journey for MS patients is varied and complex. To date, the MS market…

In a landmark FDA ruling, Ocrevus became the first DMT approved for the treatment of PP-MS in March 2017. Although the drug’s efficacy appears more modest than in patients with relapsing forms of…

Ocrevus is the 15th disease-modifying therapy (DMT) to launch for the treatment of relapsing forms of multiple sclerosis (MS) in the United States. Its novel B-cell-depleting mechanism offers…

With its launch in August 2016, Zinbryta became the 14thdisease-modifying therapy (DMT) approved to treat relapsing forms of multiple sclerosis (MS) in the United States. The monoclonal antibody…

Multiple Sclerosis | Emerging Therapies | Zinbryta | US is a three-wave series that tracks the introduction of Zinbryta for the treatment of multiple sclerosis (MS). The series is based on primary…